Table III.

Changes of PA IgG before and after treatment in three groups of refractory patients (%).

Groups	Before treatment	After treatment	χ2 test	P-value
Rituximab group (n=79)	83±12	46±12	19.38	<0.001
Cyclophosphamide group (n=86)	84±12	50±13a	17.82	<0.001
Combined therapy group (n=84)	83±14	33±9a,b	27.52	<0.001
F-value	0.174	50.71
P-value	0.840	<0.001

^aP<0.05, compared with rituximab group

^bP<0.05, compared with cyclophosphamide group.